Brasília --:--:--
World

Experimental pancreatic cancer pill halts tumor growth in most patients

A once-daily experimental pill taken with chemotherapy stopped tumor growth in about 90% of patients tested, and some tumors vanished on scans.

Before-and-after CT scans showing pancreatic tumors during experimental treatment
Illustrative photo: David P Howard  / CC BY-SA 2.0

An experimental pill against pancreatic cancer has put medicine in front of one of the most anticipated results in the field. Specialists described the clinical trial results for daraxonrasib, an experimental drug, as one of the biggest advances in treating this disease in decades. The article was published in Brazil on November 20, 2026.

The drug is taken once a day in pill form and was tested in combination with chemotherapy. According to the data presented, it stopped tumor growth in about 90% of the patients evaluated. In some cases the response was even stronger: the tumors no longer appeared on scans.

Scans show tumors that no longer appear

Before-and-after CT scans released with the results show patients treated with daraxonrasib combined with the chemotherapy drugs gemcitabine and nab-paclitaxel. The images taken before therapy show several tumors. In the images taken afterward, those same areas are no longer visible. The comparison was released with credit to the Memorial Sloan Kettering Cancer Center.

The impact lies in that combination of numbers and images. When a treatment reduces the disease enough to remove tumors from the scan, the conversation shifts from survival to the body's real response to treatment.

Still experimental, not yet a drug in pharmacies

Caution is warranted. Daraxonrasib is still in the testing phase. The results are promising, but the source does not describe the drug as approved for general use. The next step is to monitor how long the response lasts and whether it holds in a larger group of patients.

What the result could mean beyond Brazil

Pancreatic cancer is notoriously difficult to treat, which is why any result that shrinks tumors in most patients draws attention from doctors, patients and families. For readers outside Brazil, the key point is the shift the article describes: research that was once discussed in general terms is now showing concrete results. The source does not provide approval timelines, pricing or regulatory status outside Brazil, so those questions remain open. The article closes with the question that matters most to patients: whether this advance will reach routine treatment.

Translated and adapted from the original report by Visão da Direita (Portuguese). Read the original in Portuguese · Leer en español

Liked it? Share this story with your friendsShare on WhatsApp
Brazilian Senate chamber during a vote on the government's fiscal adjustment packageNext storyLula bets on Senate chief to save Brazil’s fiscal packageRead now →
#pancreatic cancer#daraxonrasib#cancer treatment#clinical trials#Brazil news

More news